| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.11B | +113.1% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 10.0% | Net margin -6.2% |
| Revenue Q/Q | +36.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.10B | 90.0% |
| R&D | ¥0.00B | 4.4% |
| SG&A | ¥0.01B | 11.6% |
| Tax & other | ¥0.00B | 0.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
沃森生物 ・ 盈康生命 ・ 宋城演艺 ・ 南方泵业 ・ 汤臣倍健 ・ *ST香雪 ・ 天舟文化 ・ 睿智医药 ・ 世纪瑞尔 ・ 昌红科技 ・ *ST动力 ・ 科泰电源
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies